You are here

BI 1584862

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy

Drugs.com

Tue, 05/6/25 - 09:34 pm

Boehringer Ingelheim

clinical trials

geographic atrophy